Baiyang Pharma plans to introduce innovative drugs for idiopathic pulmonary fibrosis.

Reporters have learned that Baiyang Medicine has announced a strategic cooperation agreement with Tianjin Jikun Medical Technology Co., Ltd.; according to the agreement, when Jikun Medical's research product JK1033 reaches a certain stage of development, Baiyang Medicine has the right to acquire JK1033 at a reasonable and mutually agreed price. JK1033 is a small molecule compound that treats idiopathic pulmonary fibrosis through a new mechanism of action. Baiyang Medicine also revealed that the company plans to strategically invest in Jikun Medical, intending to hold 24% of its equity.